We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 01:00:00 |
From May 2019 to May 2024
By Josh Beckerman
Mylan NV (MYL) said a federal appeals court affirmed prior decisions in the company's favor in a patent dispute with Teva Pharmaceutical Industries Ltd. (TEVA).
Last year, Mylan received U.S. Food and Drug Administration approval to sell glatiramer acetate injection, a generic version of Teva's blockbuster Copaxone drug, which treats multiple sclerosis.
Mylan said the appeals court affirmed that Teva's 40 mg/ML dosing patents are invalid.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 12, 2018 13:15 ET (17:15 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
